BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9863870)

  • 1. Selective vertical transmission of HIV-1 antiretroviral resistance mutations.
    Colgrove RC; Pitt J; Chung PH; Welles SL; Japour AJ
    AIDS; 1998 Dec; 12(17):2281-8. PubMed ID: 9863870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.
    Welles SL; Pitt J; Colgrove R; McIntosh K; Chung PH; Colson A; Lockman S; Fowler MG; Hanson C; Landesman S; Moye J; Rich KC; Zorrilla C; Japour AJ
    AIDS; 2000 Feb; 14(3):263-71. PubMed ID: 10716502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants.
    Kamkamidze G; Sullivan T; Charbonneau T
    J Clin Virol; 2001 Aug; 22(1):143-8. PubMed ID: 11418362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort.
    Masquelier B; Chaix ML; Burgard M; Lechenadec J; Doussin A; Simon F; Cottalorda J; Izopet J; Tamalet C; Douard D; Fleury H; Mayaux MJ; Blanche S; Rouzioux C;
    J Acquir Immune Defic Syndr; 2001 Jun; 27(2):99-104. PubMed ID: 11404530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance mutations among HIV-1 strains from antiretroviral-naive patients in Martinique, French West Indies.
    Césaire R; Dos Santos G; Abel S; Bera O; Sobesky G; Cabié A
    J Acquir Immune Defic Syndr; 1999 Dec; 22(4):401-5. PubMed ID: 10634203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.
    Rey D; Hughes M; Pi JT; Winters M; Merigan TC; Katzenstein DA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):203-8. PubMed ID: 9495218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.
    Yerly S; Rakik A; De Loes SK; Hirschel B; Descamps D; Brun-Vézinet F; Perrin L
    J Virol; 1998 May; 72(5):3520-3. PubMed ID: 9557630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of perinatal short-course zidovudine on the clinical and virological manifestations of HIV-1 subtype E infection in infants.
    Sutthent R; Chokephaibulkit K; Piyasujabul D; Vanprapa N; Roogpisuthipong A; Chaisilwatana P
    J Clin Virol; 2002 Jul; 25(1):47-56. PubMed ID: 12126721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
    van der Hoek L; Back N; Jebbink MF; de Ronde A; Bakker M; Jurriaans S; Reiss P; Parkin N; Berkhout B
    J Virol; 2005 Mar; 79(6):3536-43. PubMed ID: 15731248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains.
    Goudsmit J; Weverling GJ; van der Hoek L; de Ronde A; Miedema F; Coutinho RA; Lange JM; Boerlijst MC
    AIDS; 2001 Nov; 15(17):2293-301. PubMed ID: 11698703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of the T215Y mutation in human immunodeficiency virus type 1-infected pregnant women in a New York cohort, 1995--1999.
    Sitnitskaya Y; Rochford G; Rigaud M; Essajee S; Pollack H; Krasinski K; Borkowsky W
    Clin Infect Dis; 2001 Jul; 33(1):e3-7. PubMed ID: 11389511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the Q207D mutation in HIV type 1 reverse transcriptase on zidovudine susceptibility and replicative fitness.
    Lu J; Whitcomb J; Kuritzkes DR
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):20-3. PubMed ID: 16123676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades.
    Palumbo P; Holland B; Dobbs T; Pau CP; Luo CC; Abrams EJ; Nesheim S; Vink P; Respess R; Bulterys M;
    J Infect Dis; 2001 Nov; 184(9):1120-6. PubMed ID: 11598834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.
    Johnson VA; Petropoulos CJ; Woods CR; Hazelwood JD; Parkin NT; Hamilton CD; Fiscus SA
    J Infect Dis; 2001 Jun; 183(11):1688-93. PubMed ID: 11343221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
    Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.